Letter to Secretary Sebelius on ACA Allowance of Drug Co-Pay Programs
167 Organizations and 513 Individuals Signed on to Letter to Secretary Sebelius on the Allowance of Co-pay Assistance in the ACA Health Plans
Letter Urging UNITAID to Prioritize HIV/HCV Coinfection
TAG and 134 other organizations sent this letter to underscore the need for a swift response from UNITAID to hepatitis C virus (HCV) coinfection; delays will cost lives and impede scale-up when more effective and tolerable therapies are available.
Community Advocates Letter to U.S. Government Partners of the Conference on Retroviruses and Opportunistic Infections
We are writing to express serious concern and dismay regarding the shutting down of the website for the Conference on Retroviruses and Opportunistic Infections (CROI).
Broad Coalition of HIV/AIDS Advocates and Advocacy Organizations Urge Patient Groups to Support AllTrials Initiative
A broad coalition of HIV/AIDS advocates and advocacy organizations urge patient groups to support the AllTrials Initiative.
Tenefovir Alafenamide Fumarate (TAF) Sign-On Letter to Gilead
TAG and Other Orgs Issued this letter to Gilead about TAF.
Marketing and Use of QuantiFERON-TB Gold
14 May 2013 Peer M. Schatz Chief Executive Officer and Managing Director QIAGEN Benelux B.V. Spoorstraat 50 5911 KJ Venlo The Netherlands Email: peer.schatz@qiagen.com RE: Marketing and Use of QuantiFERON-TB Gold for active TB in India and high TB burden…
Micardis Sign-on Letter to Boehringer Ingelheim
Letter urging the company to reconsider its negative decision to provide free telmisartan (Micardis) and matching placebo to the AIDS Clinical Trials Group so that it may move forward with Study A5317.
Washington Call for Access to HCV Diagnostics, Treatment and Care for All!
Letter from TAG and civil society organizations undersigned grassroots civil society groups and non-governmental organizations asking for universal access to HCV voluntary testing and treatment.
TAG and the TB CAB Send Open Letter to Otsuka
TAG and the TB CAB send open letter to Otsuka to expedite plans to develop a pre-approval access program for delamanid for patients in urgent need, determine if delamanid is safe to use with bedaquiline, and develop the drug for pediatric use as rapidly and safely as possible.
TAG and TB CAB Issue Open Letter to Janssen
TAG and TB CAB issue an open letter to Janssen, bedaquiline’s sponsor, about the need to accelerate pediatric research, to determine the safety of using bedaquiline and delamanid together, and to support Janssen’s compassionate use program to provide access to bedaquiline for people in urgent need in places where the drug has not yet been approved.